This trial is active, not recruiting.

Condition end stage renal disease
Sponsor National Taiwan University Hospital
Start date December 2009
End date June 2010
Trial size 300 participants
Trial identifier NCT01045785, 200912018R


The purpose of this study is to determine whether aspirin resistance has impact on cardiovascular event in dialysis patient.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective cross-sectional
PFA Col/EPI normal
PFA Col/epi showed resistance

Primary Outcomes

cardiovascular event, bleeding event,and thrombosis
time frame: 1 year

Eligibility Criteria

Male or female participants at least 20 years old.

Inclusion Criteria: - dialysis >3 months - Hb>10 g/dl & Plt > 10000 Exclusion Criteria: - using medication which interfere PFA except aspirin - terminal disease such as malignancy - active vasculitis

Additional Information

Official title Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient
Principal investigator Jenqwen Huang, MD
Description Dialysis patient inevitably suffered from uremic bleeding although improvement of dialysis care in the past decades. Physicians used to check bleeding time as a surrogate marker for uremic bleeding. However, bleeding time isn't accurate and as well known, is poorly correlated with clinical bleeding such as surgical bleeding. Platelet function assay (PFA) is a newly developed method to measure platelet aggregation in vitro and is validated in many sorts of platelet disorders. Recently, PFA was also used to evaluate aspirin responsiveness in patients who had taken aspirin. Our study is aim to investigate uremic thrombocytopathy via PFA of dialysis patient in Taiwan. Furthermore, we will study aspirin resistance in dialysis patient.
Trial information was received from ClinicalTrials.gov and was last updated in January 2010.
Information provided to ClinicalTrials.gov by National Taiwan University Hospital.